Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant and Adjuvant Therapy for Triple Negative Breast Cancer
2022-501382-49-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoints: Pathological complete response (pCR) rate (ypT0/Tis ypN0) and Event-free survival (EFS). Started Mar 2017; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2022-501382-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501382-49-00.